This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6wmh
From Proteopedia
(Difference between revisions)
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Next generation monomeric IgG4 Fc== | |
| + | <StructureSection load='6wmh' size='340' side='right'caption='[[6wmh]], [[Resolution|resolution]] 2.30Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6wmh]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WMH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WMH FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wmh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wmh OCA], [https://pdbe.org/6wmh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wmh RCSB], [https://www.ebi.ac.uk/pdbsum/6wmh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wmh ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/IGHG4_HUMAN IGHG4_HUMAN] | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life. | ||
| - | + | In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.,Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. PMID:34497355<ref>PMID:34497355</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Dall'Acqua | + | <div class="pdbe-citations 6wmh" style="background-color:#fffaf0;"></div> |
| - | [[Category: Oganesyan | + | == References == |
| - | [[Category: Shan | + | <references/> |
| - | [[Category: Van Dyk | + | __TOC__ |
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Dall'Acqua WF]] | ||
| + | [[Category: Oganesyan VY]] | ||
| + | [[Category: Shan L]] | ||
| + | [[Category: Van Dyk N]] | ||
Current revision
Next generation monomeric IgG4 Fc
| |||||||||||
